Kohlberg Kravis Roberts & Co. L.P. Coherus Bio Sciences, Inc. Transaction History
Kohlberg Kravis Roberts & Co. L.P.
- $1.54 Billion
- Q4 2024
A detailed history of Kohlberg Kravis Roberts & Co. L.P. transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Kohlberg Kravis Roberts & Co. L.P. holds 3,036,076 shares of CHRS stock, worth $3.49 Million. This represents 0.27% of its overall portfolio holdings.
Number of Shares
3,036,076
Previous 3,036,076
-0.0%
Holding current value
$3.49 Million
Previous $3.16 Million
32.69%
% of portfolio
0.27%
Previous 0.18%
Shares
2 transactions
Others Institutions Holding CHRS
# of Institutions
130Shares Held
67.8MCall Options Held
1.68MPut Options Held
91.8K-
Black Rock Inc. New York, NY11.8MShares$13.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$12.8 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.28MShares$6.08 Million0.02% of portfolio
-
Rubric Capital Management LP New York, NY5.26MShares$6.05 Million0.12% of portfolio
-
Tang Capital Management LLC San Diego, CA3.65MShares$4.2 Million0.38% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $89.4M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...